Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment

Keyphrases

• Cyclophosphamide 100%
• Community-acquired Pneumonia 100%
• Advanced Thyroid Cancer 100%
• Differentiated Thyroid Carcinoma 100%
• Cisplatin-based Chemotherapy 100%
• I-131 100%
• Progression-free Survival 50%
• Overall Survival 50%
• Targeted Therapy 50%
• Disease Progression 50%
• Clinical Response 50%
• Lung Metastasis 50%
• Partial Remission 50%
• Doxorubicin 50%
• Follow-up Time 50%
• Neutropenia 50%
• Cisplatin 50%
• Adriamycin 50%
• Stable Disease 50%
• Partial Response 50%
• Treatment-related Mortality 50%
• Neuropathy 50%
• Febrile Neutropenia 50%
• Radioactive Iodine 50%
• Antiangiogenic Agents 50%
• Advanced Differentiated Thyroid Cancer 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Cisplatin 100%
• Chemotherapy 100%
• Iodine-131 100%
• Differentiated Thyroid Cancer 100%
• Doxorubicin 66%
• Cyclophosphamide 66%
• Community Acquired Pneumonia 66%
• Thyroid Cancer 66%
• Neuropathy 33%
• Remission 33%
• Disease Exacerbation 33%
• Lung Metastasis 33%
• Overall Survival 33%
• Progression Free Survival 33%
• Radioactive Iodine 33%
• Disease 33%
• Neutropenia 33%
• Isoprenaline 33%
• Angiogenesis Inhibitor 33%
• Febrile Neutropenia 33%